

Transforming women's health through innovation

Company overview

Mithra is a Belgian **biotech company** created in 1999 dedicated to transforming **Women's Health** by offering new choices through innovation based on a unique molecule called Estetrol (E4), a native estrogen that offers a differentiated benefit/risk profile compared to existing hormone-based solutions.

Thanks to the commitment of its employees based on two sites, among which a majority of women, Mithra stands by its goals to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span.

Mithra relies on **two complementary innovative platforms**: an Estetrol-based portfolio and Complex Therapeutics which are complemented by a unique manufacturing facility, Mithra CDMO and leveraged by Mithra's know-how in **long-acting drug development** using polymer technology.

Global strategy

Women's health

Estelle® is a contraceptive pill designed to improve women's contraceptive experience as it showed a favorable safety profile, a higher user satisfaction with improved quality of life and a low risk of drug-drug interaction.

Donesta® is a next generation orally-administrated estetrol-based hormone therapy product candidate.

and beyond

Neuroprotection and wound healing.

Complex therapeutics

Myring® Contraception

Tibelia® Menopause

Zoreline® Oncology

R&D pipeline

	Product	Indication	Preclinical	Phase I	Phase II	Phase III	Commercialization	
E4	Estelle®	Contraception	[Progress bar spanning Preclinical, Phase I, Phase II, Phase III, and Commercialization]					
	Donesta®	Menopause	[Progress bar spanning Preclinical, Phase I, Phase II, and Phase III]					
	-	Neuroprotection	[Progress bar spanning Preclinical and Phase I]					
	-	Wound healing	[Progress bar spanning Preclinical]					
COMPLEX THERAPEUTICS	Myring®	Contraception	[Progress bar spanning Preclinical, Phase I, Phase II, Phase III, and Commercialization]					
	Tibelia®	Menopause	[Progress bar spanning Preclinical, Phase I, Phase II, Phase III, and Commercialization]					
	Zoreline®	Oncology	[Progress bar spanning Preclinical]					

Management



David Horn Solomon
Chief Executive Officer (CEO)



Christophe Maréchal
Chief Financial Officer (CFO)




Alex Sokolowski
Head of Investor Relations

ESG Rating




Financial overview

(in EUR million)



Share information

Number of outstanding shares



Shareholders

(19 February 2023)

Noshaq	7.94 %
Armistice Capital	14.47 %
François Fornieri	15.64 %
Other shareholders (<5%)	61.95 %

Cash position



Analyst Coverage



Last updated Feb 2024



Stay in touch!

Subscribe to our mailing list:
www.mithra.com/en/newsletter/



Further information

investorrelations@mithra.com
<https://www.mithra.com/en/investors/>